7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC

Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity. In PAPILLON (NCT04538664), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo (median, 11.4 vs 6.7 months [mo]; HR, 0.40; [95% CI, 0.30–0.53]; P<0.001; Zhou NEJM 2023). We evaluated time to symptomatic progression (TTSP) and patient-reported outcomes (PROs) from PAPILLON.